Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (40 quarters reported)
$366M in Q3 2016 → $1.54B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Generate Biomedicines Inc | 68.7% | Unchanged | 62,673,117 | $1.06B |
| Moderna Inc | 21.1% | Unchanged | 4,632,149 | $324M |
| Sana Biotechnology Inc | 5.7% | Unchanged | 25,001,856 | $87.3M |
| Foghorn Therapeutics Inc | 4.0% | Unchanged | 12,674,120 | $61.8M |
| Seres Therapeutics Inc | 0.6% | Unchanged | 1,155,850 | $9.12M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
No position changes this quarter.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Generate Biomedicines Inc | New | +62,673,117 | +$783M | 67.4% |
quarter ended December 31, 2025 · filed February 17, 2026
No position changes this quarter.
quarter ended September 30, 2025 · filed November 14, 2025
No position changes this quarter.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Seres Therapeutics Inc | Exited | −23,117,045 | −$16.2M | — |
| Seres Therapeutics Inc | New | +1,155,850 | +$12.8M | 4.8% |
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Omega Therapeutics Inc | Exited | −29,225,579 | −$21.8M | — |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Syros Pharmaceuticals Inc | Exited | −1,293,849 | −$2.78M | — |
quarter ended September 30, 2024 · filed November 14, 2024
No position changes this quarter.
Loading...
